Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7483443 | 0.96 | LRP6 (0.34) | MAPTKMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL891063 | 0.93 | LRP6 (0.33) | MAPTKMT2AALDH1A1RAB9AGABRG2 | |
| SCHEMBL7473791 | 0.92 | NPC1 (0.33) | MAPTKMT2AALDH1A1RAB9AHPGD | |
| SCHEMBL13693075 | 0.91 | MAPT (0.37) | MAPTKMT2AALDH1A1RAB9AHPGD | |
| SCHEMBL1845080 | 0.90 | KEAP1 (0.38) | MAPTKMT2AALDH1A1NR4A1RAB9A | |
| SCHEMBL5550993 | 0.90 | MAPT (0.38) | MAPTKMT2AALDH1A1NR4A1RAB9A | |
| SCHEMBL1847688 | 0.90 | GABRG2 (0.37) | MAPTKMT2AALDH1A1RAB9AHPGD | |
| SCHEMBL7479868 | 0.90 | MEN1 (0.40) | MAPTKMT2AALDH1A1RAB9AGABRG2 | |
| SCHEMBL5549293 | 0.88 | MAPT (0.39) | MAPTKMT2AALDH1A1NR4A1RAB9A | |
| SCHEMBL7971698 | 0.87 | MAPT (0.38) | MAPTKMT2AALDH1A1NR4A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166357-B2 | Photochromic articles that activate behind ultraviolet radiation blocking transparencies and methods for preparation | TRANSITIONS OPTICAL, INC. (US) | 2007-01-23 | — | — | US | claimed |
| US-20040185268-A1 | Photochromic articles that activate behind ultraviolet radiation blocking transparencies and methods for preparation | TRANSITIONS OPTICAL LIMITED (IE) | 2004-09-23 | — | — | US | claimed |
| US-7521004-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2009-04-21 | — | — | US | disclosed |
| US-7521004-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1674460-B1 | CHROMENE COMPOUND | TOKUYAMA CORP (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20070215844-A1 | Chromene Compound | TOKUYAMA CORPORATION (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070215844-A1 | Chromene Compound | TOKUYAMA CORPORATION (JP) | 2007-09-20 | — | — | US | disclosed |
| US-7166357-B2 | Photochromic articles that activate behind ultraviolet radiation blocking transparencies and methods for preparation | TRANSITIONS OPTICAL, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20040185268-A1 | Photochromic articles that activate behind ultraviolet radiation blocking transparencies and methods for preparation | TRANSITIONS OPTICAL LIMITED (IE) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070215844-A1 | Chromene Compound | CRY2, TYR, CRY1 | MAPT 520/4885KMT2A 411/4885ALDH1A1 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.